Bulletin
Investor Alert

press release

Jan. 3, 2022, 8:01 a.m. EST

Intra-Cellular Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. /zigman2/quotes/209441868/composite ITCI -6.05% , a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 am ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com . Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com .

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
cradinovic@burnsmc.com
212-213-0006

COMTEX_399975931/2471/2022-01-03T08:00:44

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/209441868/composite
US : U.S.: Nasdaq
$ 53.57
-3.45 -6.05%
Volume: 1.48M
Aug. 12, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.05 billion
Rev. per Employee
$270,416
loading...

Partner Center

Link to MarketWatch's Slice.